The 5-alpha reductase deficiency market size has grown strongly in recent years. It will grow from $1.29 billion in 2023 to $1.39 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth observed in the historical period can be attributed to several factors, including investments in research and development, the regulatory landscape influencing healthcare practices, the development and improvement of healthcare infrastructure, increased awareness and educational efforts, and expanded health insurance coverage. These combined elements have played a significant role in shaping the growth trajectory within the specified historic period.
The 5-alpha reductase deficiency market size is expected to see strong growth in the next few years. It will grow to $1.94 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The anticipated growth in the forecast period can be attributed to various factors, including innovations in therapeutics, advances in genetic research, the emergence of precision medicine, global health initiatives, and the integration of gene therapies. Significant trends expected in the forecast period encompass advancements in treatment options, diagnostic innovations, the adoption of patient-centric approaches in healthcare, developments in the regulatory landscape, and considerations related to market access and affordability.
The escalating number of research and development endeavors in genomics is significantly contributing to the growth trajectory of the 5-alpha reductase deficiency market. Genomics, involving the comprehensive study of an individual's entire genome, including the interplay between genes and their environment, serves as a pivotal tool in diagnosing 5-alpha reductase deficiency by pinpointing specific genetic mutations responsible for the condition. Consequently, the surge in research and development activities within genomics is poised to play a crucial role in not only uncovering but also treating this disorder. As detailed in the 'Accelerating Access to Genomics for Global Health' report by the World Health Organization (WHO) in July 2022, the percentage of nations equipped to perform genomic surveillance surged from 54% to 68% between March 2021 and January 2022. Therefore, the burgeoning research and development efforts in genomics are forecasted to be a primary driver propelling the 5-alpha reductase deficiency market.
The mounting prevalence of genetic and rare diseases stands poised to propel the growth trajectory of the 5-alpha reductase deficiency market in the forthcoming years. Genetic and rare diseases, arising from alterations in an individual's genes and being uncommon within the general populace, highlight the intricate role of genetic factors in human development, especially concerning sexual differentiation, exemplified by 5-alpha reductase deficiency. As noted in November 2022 by the Australian Government Department of Health, approximately 7,000 rare illnesses, either fatal or severely disabling, exist. These rare diseases impact about 8% of Australians, totaling around 2 million individuals, with roughly 80% being genetic in nature. Consequently, the escalating prevalence of genetic and rare diseases constitutes a pivotal factor propelling the 5-alpha reductase deficiency market.
The emergence of innovative genetic testing methodologies for diagnosing rare diseases constitutes a key trend in the 5-alpha reductase deficiency market. Leading entities operating within this domain are directing their efforts toward developing pioneering genetic testing solutions that efficiently diagnose rare conditions such as 5-alpha reductase deficiency, particularly in their nascent stages. These advancements in diagnostics not only offer a competitive advantage to major market players but also enhance their position in the market. For instance, in June 2022, Avesthagen Limited, a US-based integrated systems biology platform company, unveiled its latest genetic testing portfolio. The genome panels encompassed in this portfolio present highly specialized, disease-centric analyses tailored for rare genetic diseases, thereby showcasing significant strides in the diagnostic landscape.
Leading companies within the 5-alpha reductase deficiency market are pursuing a strategic partnership approach to facilitate the commercialization of Finjuve (finasteride) across the Middle East and North Africa (MENA). Strategic partnerships involve the collaborative utilization of each other's strengths and resources to achieve mutual benefits and success. In November 2021, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, disclosed a licensing agreement with Almirall S.A. to introduce Finjuve to selected MENA countries' markets. Finjuve, a finasteride spray, is licensed for the medical management of androgenetic alopecia in Germany, Italy, Luxembourg, and Portugal. According to the terms of this licensing agreement, Hikma will oversee product registration and commercialization in specific MENA regions, while Almirall will manage product supply. This alliance serves to broaden Hikma's presence in dermatology, a crucial therapeutic sector, and diversifies its portfolio with a unique product. Almirall S.A. operates as a pharmaceutical company based in Spain.
In April 2023, Blue Water Vaccines Inc., a US-based biopharmaceutical firm, completed the acquisition of ENTADFI (finasteride/tadalafil) from Veru Inc. for an approximate sum of $100 million. This acquisition significantly expands the company's scope across various pharmaceutical sectors. By acquiring ENTADFI, Blue Water gains entry into the commercial domain while also mitigating expenditure and securing crucial revenue streams for the vaccine candidate pipeline. Despite this expansion, Blue Water remains steadfast in its primary mission of aiding individuals in need and is eager to enhance this asset and the pipeline for patients worldwide. Veru Inc. functions as a US-based biopharmaceutical company.
Major companies operating in the 5-alpha reductase deficiency market report are Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Sanofi SA, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Alma Lasers Ltd., Viveve Medical Inc., Fotona d.o.o, Almirall SA, Hologic Inc., Gilead Sciences Inc., Johnson & Johnson Services Inc., Mallinckrodt Pharmaceuticals, Mylan N.V., Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Roivant Sciences Ltd., Sanofi Genzyme, Shionogi & Co. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Vertex Pharmaceuticals Incorporated, Zoetis Inc., Cadila Healthcare Limited, Endo International plc.
North America was the largest region in the 5-alpha reductase deficiency market in 2023. The regions covered in the 5-alpha reductase deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the 5-alpha reductase deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary diagnostic methods for 5-alpha reductase deficiency include chromosome analysis, gene sequencing, hormone tests, imaging tests, and genetic screening, among others. Chromosome analysis is employed to determine the patient's chromosomal makeup, distinguishing between XX (Female) and XY (Male) chromosomes. Various treatments are available for 5-alpha reductase deficiency, including surgery, vaginoplasty, feminizing genitoplasty, hormone replacement therapy, and other interventions. End-users of these treatments include hospitals, specialty clinics, and other medical facilities.
The 5-alpha reductase deficiency market research report is one of a series of new reports that provides 5-alpha reductase deficiency market statistics, including 5-alpha reductase deficiency industry global market size, regional shares, competitors with a 5-alpha reductase deficiency market share, detailed 5-alpha reductase deficiency market segments, market trends and opportunities, and any further data you may need to thrive in the 5-alpha reductase deficiency industry. This 5-alpha reductase deficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The 5-alpha reductase deficiency market size is expected to see strong growth in the next few years. It will grow to $1.94 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The anticipated growth in the forecast period can be attributed to various factors, including innovations in therapeutics, advances in genetic research, the emergence of precision medicine, global health initiatives, and the integration of gene therapies. Significant trends expected in the forecast period encompass advancements in treatment options, diagnostic innovations, the adoption of patient-centric approaches in healthcare, developments in the regulatory landscape, and considerations related to market access and affordability.
The escalating number of research and development endeavors in genomics is significantly contributing to the growth trajectory of the 5-alpha reductase deficiency market. Genomics, involving the comprehensive study of an individual's entire genome, including the interplay between genes and their environment, serves as a pivotal tool in diagnosing 5-alpha reductase deficiency by pinpointing specific genetic mutations responsible for the condition. Consequently, the surge in research and development activities within genomics is poised to play a crucial role in not only uncovering but also treating this disorder. As detailed in the 'Accelerating Access to Genomics for Global Health' report by the World Health Organization (WHO) in July 2022, the percentage of nations equipped to perform genomic surveillance surged from 54% to 68% between March 2021 and January 2022. Therefore, the burgeoning research and development efforts in genomics are forecasted to be a primary driver propelling the 5-alpha reductase deficiency market.
The mounting prevalence of genetic and rare diseases stands poised to propel the growth trajectory of the 5-alpha reductase deficiency market in the forthcoming years. Genetic and rare diseases, arising from alterations in an individual's genes and being uncommon within the general populace, highlight the intricate role of genetic factors in human development, especially concerning sexual differentiation, exemplified by 5-alpha reductase deficiency. As noted in November 2022 by the Australian Government Department of Health, approximately 7,000 rare illnesses, either fatal or severely disabling, exist. These rare diseases impact about 8% of Australians, totaling around 2 million individuals, with roughly 80% being genetic in nature. Consequently, the escalating prevalence of genetic and rare diseases constitutes a pivotal factor propelling the 5-alpha reductase deficiency market.
The emergence of innovative genetic testing methodologies for diagnosing rare diseases constitutes a key trend in the 5-alpha reductase deficiency market. Leading entities operating within this domain are directing their efforts toward developing pioneering genetic testing solutions that efficiently diagnose rare conditions such as 5-alpha reductase deficiency, particularly in their nascent stages. These advancements in diagnostics not only offer a competitive advantage to major market players but also enhance their position in the market. For instance, in June 2022, Avesthagen Limited, a US-based integrated systems biology platform company, unveiled its latest genetic testing portfolio. The genome panels encompassed in this portfolio present highly specialized, disease-centric analyses tailored for rare genetic diseases, thereby showcasing significant strides in the diagnostic landscape.
Leading companies within the 5-alpha reductase deficiency market are pursuing a strategic partnership approach to facilitate the commercialization of Finjuve (finasteride) across the Middle East and North Africa (MENA). Strategic partnerships involve the collaborative utilization of each other's strengths and resources to achieve mutual benefits and success. In November 2021, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, disclosed a licensing agreement with Almirall S.A. to introduce Finjuve to selected MENA countries' markets. Finjuve, a finasteride spray, is licensed for the medical management of androgenetic alopecia in Germany, Italy, Luxembourg, and Portugal. According to the terms of this licensing agreement, Hikma will oversee product registration and commercialization in specific MENA regions, while Almirall will manage product supply. This alliance serves to broaden Hikma's presence in dermatology, a crucial therapeutic sector, and diversifies its portfolio with a unique product. Almirall S.A. operates as a pharmaceutical company based in Spain.
In April 2023, Blue Water Vaccines Inc., a US-based biopharmaceutical firm, completed the acquisition of ENTADFI (finasteride/tadalafil) from Veru Inc. for an approximate sum of $100 million. This acquisition significantly expands the company's scope across various pharmaceutical sectors. By acquiring ENTADFI, Blue Water gains entry into the commercial domain while also mitigating expenditure and securing crucial revenue streams for the vaccine candidate pipeline. Despite this expansion, Blue Water remains steadfast in its primary mission of aiding individuals in need and is eager to enhance this asset and the pipeline for patients worldwide. Veru Inc. functions as a US-based biopharmaceutical company.
Major companies operating in the 5-alpha reductase deficiency market report are Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Sanofi SA, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Alma Lasers Ltd., Viveve Medical Inc., Fotona d.o.o, Almirall SA, Hologic Inc., Gilead Sciences Inc., Johnson & Johnson Services Inc., Mallinckrodt Pharmaceuticals, Mylan N.V., Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Roivant Sciences Ltd., Sanofi Genzyme, Shionogi & Co. Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Vertex Pharmaceuticals Incorporated, Zoetis Inc., Cadila Healthcare Limited, Endo International plc.
North America was the largest region in the 5-alpha reductase deficiency market in 2023. The regions covered in the 5-alpha reductase deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the 5-alpha reductase deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary diagnostic methods for 5-alpha reductase deficiency include chromosome analysis, gene sequencing, hormone tests, imaging tests, and genetic screening, among others. Chromosome analysis is employed to determine the patient's chromosomal makeup, distinguishing between XX (Female) and XY (Male) chromosomes. Various treatments are available for 5-alpha reductase deficiency, including surgery, vaginoplasty, feminizing genitoplasty, hormone replacement therapy, and other interventions. End-users of these treatments include hospitals, specialty clinics, and other medical facilities.
The 5-alpha reductase deficiency market research report is one of a series of new reports that provides 5-alpha reductase deficiency market statistics, including 5-alpha reductase deficiency industry global market size, regional shares, competitors with a 5-alpha reductase deficiency market share, detailed 5-alpha reductase deficiency market segments, market trends and opportunities, and any further data you may need to thrive in the 5-alpha reductase deficiency industry. This 5-alpha reductase deficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. 5-Alpha Reductase Deficiency Market Characteristics3. 5-Alpha Reductase Deficiency Market Trends and Strategies31. Global 5-Alpha Reductase Deficiency Market Competitive Benchmarking32. Global 5-Alpha Reductase Deficiency Market Competitive Dashboard33. Key Mergers and Acquisitions in the 5-Alpha Reductase Deficiency Market
4. 5-Alpha Reductase Deficiency Market - Macro Economic Scenario
5. Global 5-Alpha Reductase Deficiency Market Size and Growth
6. 5-Alpha Reductase Deficiency Market Segmentation
7. 5-Alpha Reductase Deficiency Market Regional and Country Analysis
8. Asia-Pacific 5-Alpha Reductase Deficiency Market
9. China 5-Alpha Reductase Deficiency Market
10. India 5-Alpha Reductase Deficiency Market
11. Japan 5-Alpha Reductase Deficiency Market
12. Australia 5-Alpha Reductase Deficiency Market
13. Indonesia 5-Alpha Reductase Deficiency Market
14. South Korea 5-Alpha Reductase Deficiency Market
15. Western Europe 5-Alpha Reductase Deficiency Market
16. UK 5-Alpha Reductase Deficiency Market
17. Germany 5-Alpha Reductase Deficiency Market
18. France 5-Alpha Reductase Deficiency Market
19. Italy 5-Alpha Reductase Deficiency Market
20. Spain 5-Alpha Reductase Deficiency Market
21. Eastern Europe 5-Alpha Reductase Deficiency Market
22. Russia 5-Alpha Reductase Deficiency Market
23. North America 5-Alpha Reductase Deficiency Market
24. USA 5-Alpha Reductase Deficiency Market
25. Canada 5-Alpha Reductase Deficiency Market
26. South America 5-Alpha Reductase Deficiency Market
27. Brazil 5-Alpha Reductase Deficiency Market
28. Middle East 5-Alpha Reductase Deficiency Market
29. Africa 5-Alpha Reductase Deficiency Market
30. 5-Alpha Reductase Deficiency Market Competitive Landscape and Company Profiles
34. 5-Alpha Reductase Deficiency Market Future Outlook and Potential Analysis
35. Appendix
Executive Summary
5-Alpha Reductase Deficiency Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on 5-alpha reductase deficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for 5-alpha reductase deficiency? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Diagnosis: Chromosome Analysis; Gene Sequencing; Hormone Tests; Imaging Tests; Genetic Screening; Other Diagnosis
2) By Treatment: Surgery; Vaginoplasty; Feminizing Genitoplasty; Hormone Replacement Therapy; Other Treatments
3) By End-Users: Hospitals; Specialty Clinics; Other End-Users
Companies Mentioned: Merck & Co. Inc.; F. Hoffmann-La Roche Ltd.; Sanofi SA; Pfizer Inc.; GlaxoSmithKline plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Merck & Co. Inc.
- F. Hoffmann-La Roche Ltd.
- Sanofi SA
- Pfizer Inc.
- GlaxoSmithKline plc
- Novartis AG
- Bayer AG
- Eli Lilly and Company
- Alma Lasers Ltd.
- Viveve Medical Inc.
- Fotona d.o.o
- Almirall SA
- Hologic Inc.
- Gilead Sciences Inc.
- Johnson & Johnson Services Inc.
- Mallinckrodt Pharmaceuticals
- Mylan N.V.
- Novo Nordisk A/S
- Regeneron Pharmaceuticals Inc.
- Roivant Sciences Ltd.
- Sanofi Genzyme
- Shionogi & Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- UCB S.A.
- Vertex Pharmaceuticals Incorporated
- Zoetis Inc.
- Cadila Healthcare Limited
- Endo International plc
Methodology
LOADING...
